A model-supported interaction estimate must remain identifiable as a prediction.
What the supplied source reports
The PBPK analysis used laboratory information, a CYP3A induction biomarker and clinical verification involving venetoclax to develop the ivosidenib interaction model. It then predicted midazolam exposure and peak-concentration ratios of 0.18 and 0.27 after repeated ivosidenib. These are simulated comparisons with exposure without the interacting drug.
Limits of the evidence
The midazolam result was not a direct clinical coadministration measurement. Model performance depends on assumptions, parameterization and transfer from the verification dataset. Exposure reduction does not automatically specify the magnitude of lost sedation or the appropriate dose response.
Implications for forensic interpretation
For a pharmacokinetic opinion, label measured observations, fitted parameters and prospective simulations separately. Establish actual ivosidenib duration, midazolam route and clinical response. The model provides a mechanistic hypothesis and estimated interaction magnitude under its conditions, not a measured concentration ratio for a particular patient.
Source and related reading
Source reviewed: PBPK modeling to predict drug drug interactions of ivosidenib as a perpetrator in cancer patients an (PMC8213421). Forensic applications above are interpretive analysis of the supplied publication.
Related reading: Clobazam Interaction Review Shows Why Measuring the Active Metabolite Matters.
Leave a Reply